https://haliatx.com/ar https://haliatx.com https://haliatx.com/ar/internal/do-not-delete https://haliatx.com/internal/do-not-delete https://haliatx.com/ar/styleguide https://haliatx.com/styleguide https://haliatx.com/ar/news https://haliatx.com/news https://haliatx.com/ar/genmor-ia https://haliatx.com/genmor-ia https://haliatx.com/ar/impact-future-of-medicine https://haliatx.com/impact-future-of-medicine https://haliatx.com/ar/about https://haliatx.com/about https://haliatx.com/ar/genmor-platform https://haliatx.com/genmor-platform https://haliatx.com/ar/what-is-genetic-resilience https://haliatx.com/what-is-genetic-resilience https://haliatx.com/ar/halia-therapeutics-pipeline https://haliatx.com/halia-therapeutics-pipeline https://haliatx.com/ar/contact https://haliatx.com/contact https://haliatx.com/ar/privacy-policy https://haliatx.com/privacy-policy https://haliatx.com/press-releases/halia-therapeutics-announces-presentation-at-the-bio-investment-growth-summit https://haliatx.com/ar/press-releases/halia-therapeutics-announces-presentation-at-the-bio-investment-growth-summit https://haliatx.com/press-releases/halia-therapeutics-completes-enrollment-in-phase-2a-clinical-trial-of-ht-6184-for-myelodysplastic-syndrome-mds-2 https://haliatx.com/ar/press-releases/halia-therapeutics-completes-enrollment-in-phase-2a-clinical-trial-of-ht-6184-for-myelodysplastic-syndrome-mds-2 https://haliatx.com/press-releases/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-u-s-fda-for-myelodysplastic-syndromes https://haliatx.com/ar/press-releases/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-u-s-fda-for-myelodysplastic-syndromes https://haliatx.com/ar/news/blog-title-heading-will-go-here-2 https://haliatx.com/news/halia-therapeutics-awarded-novo-nordisk-golden-ticket-to-advance-obesity-and-inflammation-research https://haliatx.com/news/halia-therapeutics-announces-positive-phase-2a-data-for-ofirnoflast-in-lower-risk-mds-at-ash-2025 https://haliatx.com/ar/news/halia-therapeutics-announces-positive-phase-2a-data-for-ofirnoflast-in-lower-risk-mds-at-ash-2025 https://haliatx.com/news/halia-therapeutics-announces-presentation-at-the-bio-investment-growth-summit https://haliatx.com/ar/news/halia-therapeutics-announces-presentation-at-the-bio-investment-growth-summit https://haliatx.com/news/halia-therapeutics-ceo-dr-david-bearss-to-deliver-keynote-address-at-med-investment-forum-2025-in-abu-dhabi https://haliatx.com/ar/news/halia-therapeutics-ceo-dr-david-bearss-to-deliver-keynote-address-at-med-investment-forum-2025-in-abu-dhabi https://haliatx.com/news/halia-therapeutics-completes-enrollment-in-phase-2a-clinical-trial-of-ht-6184-for-myelodysplastic-syndrome-mds https://haliatx.com/ar/news/halia-therapeutics-completes-enrollment-in-phase-2a-clinical-trial-of-ht-6184-for-myelodysplastic-syndrome-mds https://haliatx.com/news/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation https://haliatx.com/ar/news/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation https://haliatx.com/news/halia-therapeutics-strengthens-global-genomics-leadership-with-appointment-of-paul-jones-as-chief-strategy-officer-gm-international-markets https://haliatx.com/ar/news/halia-therapeutics-strengthens-global-genomics-leadership-with-appointment-of-paul-jones-as-chief-strategy-officer-gm-international-markets https://haliatx.com/news/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference https://haliatx.com/ar/news/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference https://haliatx.com/news/halia-therapeutics-to-present-final-phase-2-ofirnoflast-data-in-lower-risk-mds-at-eha2026-and-announces-appointment-of-han-myint-md-facp-as-chief-medical-officer https://haliatx.com/ar/news/halia-therapeutics-to-present-final-phase-2-ofirnoflast-data-in-lower-risk-mds-at-eha2026-and-announces-appointment-of-han-myint-md-facp-as-chief-medical-officer https://haliatx.com/news/halia-therapeutics-to-present-groundbreaking-data-on-novel-allosteric-nek7-inhibitor-ofirnoflast-at-the-2025-american-society-of-hematology-annual-meeting https://haliatx.com/ar/news/halia-therapeutics-to-present-groundbreaking-data-on-novel-allosteric-nek7-inhibitor-ofirnoflast-at-the-2025-american-society-of-hematology-annual-meeting https://haliatx.com/news/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-u-s-fda-for-myelodysplastic-syndromes https://haliatx.com/ar/news/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-u-s-fda-for-myelodysplastic-syndromes